ArticleFrontiers in immunology2025
Biochemical analysis reveals aberrant and variable Immunoglobulin M composition in Waldenström macroglobulinemia and IgM monoclonal gammopathy of unknown significance.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Waldenström Macroglobulinemia (WM) is a rare B cell malignancy defined by greater than 10% infiltration of lymphoplasmacytic cells in the bone marrow (BM) and a circulating monoclonal Immunoglobulin M (IgM), while its precursor state IgM monoclonal gammopathy of undetermined significance (MGUS) has <10% BM infiltration. WM and IgM MGUS are unique amongst malignant lymphomas because symptoms and treatment indication may be caused by monoclonal IgM and not by the malignant cell infiltration. These symptoms correlate poorly with IgM levels, suggesting there may be specific biochemical properties of those pathological IgMs, yet IgM structure in IgM gammopathies has not been systematically studied. In healthy individuals, IgM circulates as a pentameric molecule that consists of five covalently linked monomers (H2L2 pairs), a joining (J-) chain and one CD5-Like (CD5L) molecule. In order to gain insight into structural variation of IgM in monoclonal IgM gammopathies, we developed and tested several assays to determine J-chain and CD5L content and polymerization state of IgM from 29 IgM MGUS and WM patients. In multiple cases, IgM was found to be (partially) devoid of J-chain, which associated with differential assembly of IgM into variably sized polymers. Moreover, we found that IgM exceeding ~5 g/L was no longer saturated with CD5L. Relative binding of polymeric Ig receptor varied by over 30-fold. Combined, in this pilot study we demonstrate that structural and functional variation in IgM of IgM MGUS and WM is common. These aberrations in IgM structure may relate to variations in clinical phenotype in IgM monoclonal gammopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.